Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.70)
# 680
Out of 4,765 analysts
59
Total ratings
46.34%
Success rate
9.06%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $16.25 | +16.92% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $364.44 | +7.01% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $42.17 | +30.44% | 3 | Feb 25, 2025 | |
| RGEN Repligen | Maintains: Overweight | $190 → $200 | $142.44 | +40.41% | 5 | Feb 21, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $40.64 | +35.33% | 1 | Feb 21, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $12 | $9.88 | +21.46% | 3 | Feb 13, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $35 → $40 | $39.12 | +2.25% | 1 | Feb 4, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $117.33 | +36.37% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $508.90 | +31.66% | 8 | Sep 20, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $88 → $80 | $69.81 | +14.60% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $9.70 | +106.19% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.48 | - | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,201.99 | +16.47% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $7.17 | -16.32% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $110.32 | +8.77% | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.20 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $44.97 | +100.13% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $204.09 | +32.29% | 4 | Dec 20, 2023 |
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $16.25
Upside: +16.92%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $364.44
Upside: +7.01%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $42.17
Upside: +30.44%
Repligen
Feb 21, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $142.44
Upside: +40.41%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $40.64
Upside: +35.33%
10x Genomics
Feb 13, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $9.88
Upside: +21.46%
Twist Bioscience
Feb 4, 2025
Maintains: Underweight
Price Target: $35 → $40
Current: $39.12
Upside: +2.25%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $117.33
Upside: +36.37%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $508.90
Upside: +31.66%
Henry Schein
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $69.81
Upside: +14.60%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $9.70
Upside: +106.19%
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,201.99
Upside: +16.47%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $7.17
Upside: -16.32%
Jul 30, 2024
Maintains: Neutral
Price Target: $105 → $120
Current: $110.32
Upside: +8.77%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $44.97
Upside: +100.13%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $204.09
Upside: +32.29%